Anti-Angiogenic Therapies in the Treatment of Waldenstrom's Macroglobulinemia

被引：1

作者：

Sacco, A.

Ghobrial, I. M.

Roccaro, A. M. ^{[1
,2
]}

机构：

[1] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA

[2] Harvard Univ, Sch Med, Boston, MA 02115 USA

来源：

CURRENT CANCER DRUG TARGETS | 2011年 / 11卷 / 09期

关键词：

Anti-angiogenic approach; Waldenstrom's Macroglobulinemia; IGM MONOCLONAL GAMMOPATHY; SINGLE-AGENT BORTEZOMIB; PHASE-II TRIAL; BONE-MARROW; KAPPA-B; PROTEASOME; INHIBITION; SURVIVAL; TARGET; CELLS;

D O I：

10.2174/156800911798073032

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Bone marrow microenvironment has been shown to play a crucial role in supporting the pathogenesis and the progression of several B-cell malignancies, including Waldenstrom's Macroglobulinemia (WM). Among the different cell types within the bone marrow milieu, endothelial cells have been proven to support WM cells growth. Based on the understanding of bone marrow neo-angiogenesis in plasma cell dyscrasias, a number of anti-angiogenic molecules are now available for the treatment of these diseases. Indeed, anti-angiogenic drugs, such as proteasome-, proteins kinase-C (PKC)-, phosphatidylinositol 3-kinase/mammalian target of rapamycin (mTOR)-, and histone deacetylase (HDAC)-inhibitors are now available, playing a key role in the treatment of WM both in the preclinical settings and as part of clinical trials.

引用

收藏

页码：1025 / 1029

页数：5

相关论文

共 50 条

[21] Treatment of relapsed and refractory Waldenstrom Macroglobulinemia [J].

Amaador, Karima ;

Kersten, Marie J. ;

Minnema, Monique C. ;

Vos, Josephine M., I .

LEUKEMIA & LYMPHOMA, 2023, 64 (01) :30-41

[22] Waldenstrom's macroglobulinemia [J].

Dimopoulos, MA ;

Anagnostopoulos, A .

BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY, 2005, 18 (04) :747-765

[23] How to manage Waldenstrom's macroglobulinemia [J].

Buske, C. ;

Leblond, V. .

LEUKEMIA, 2013, 27 (04) :762-772

[24] Waldenstrom's macroglobulinemia in the era of immunotherapy [J].

Vaxman, Iuliana ;

Gertz, Morie .

LEUKEMIA & LYMPHOMA, 2020, 61 (06) :1292-1304

[25] PRECLINICAL ASSESSMENT OF THE EFFICACY OF ANTI-ANGIOGENIC THERAPIES IN HEPATOCELLULAR CARCINOMA [J].

Barral, Matthias ;

Raballand, Annemilai ;

Dohan, Anthony ;

Soyer, Philippe ;

Pocard, Marc ;

Bonnin, Philippe .

ULTRASOUND IN MEDICINE AND BIOLOGY, 2016, 42 (02) :438-446

[26] Mechanisms of neovascularization and resistance to anti-angiogenic therapies in glioblastoma multiforme [J].

Soda, Yasushi ;

Myskiw, Chad ;

Rommel, Amy ;

Verma, Inder M. .

JOURNAL OF MOLECULAR MEDICINE-JMM, 2013, 91 (04) :439-448

[27] Prognostic factors and indications for treatment of Waldenstrom's Macroglobulinemia [J].

Kyle, Robert A. ;

Ansell, Stephen M. ;

Kapoor, Prashant .

BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY, 2016, 29 (02) :179-186

[28] Treatment of relapsed or refractory Waldenstrom's macroglobulinemia with bortezomib [J].

Dimopoulos, Meletios A. ;

Anagnostopoulos, Athanasios ;

Kyrtsonis, Maria Christina ;

Castritis, Efstathios ;

Bitsaktsis, Athanasios ;

Pangalis, Gerassimos A. .

HAEMATOLOGICA, 2005, 90 (12) :1655-1658

[29] Survival and prognostic factors after initiation of treatment in Waldenstrom's macroglobulinemia [J].

Dimopoulos, MA ;

Hamilos, G ;

Zervas, K ;

Symeonidis, A ;

Kouvatseas, G ;

Roussou, P ;

Gika, D ;

Karmiris, T ;

Bourantas, K ;

Zomas, A ;

Mitsouli, C ;

Xilouri, I ;

Vervessou, E ;

Matsis, K ;

Anagnostopoulos, N ;

Economopoulos, T .

ANNALS OF ONCOLOGY, 2003, 14 (08) :1299-1305

[30] Update on Anti-angiogenic Treatment for Malignant Gliomas [J].

de Groot, John F. ;

Mandel, Jacob J. .

CURRENT ONCOLOGY REPORTS, 2014, 16 (04)

← 1 2 3 4 5 →